A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study [0.03%]
伊拉克血友病经济负担的全面评估：一项基于实地的研究
Baraa Ghani Abdulraheem,Ali Azeez Al-Jumaili,Safa Mohammed Shaukat Mohammed Khalid
Baraa Ghani Abdulraheem
Background: This study assessed the economic burden of hemophilia A, B, and A with inhibitors, including direct medical, non-medical, and indirect costs from both governmental and patient perspectives. ...
Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain [0.03%]
关于西班牙开角型青光眼和高眼压症患者单剂量阳离子乳剂无防腐剂拉坦前列腺素与单剂量拉坦前列腺素治疗的成本效用分析
María Isabel Canut,Julián García-Feijoo,Jose Manuel Larrosa-Poves et al.
María Isabel Canut et al.
Background: This study evaluated the efficiency CE-latanoprost unidose (cationic emulsion of latanoprost) versus latanoprost unidose (non-emulsion formulation) in open-angle glaucoma and ocular hypertension (OAG/OHT) with...
Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer [0.03%]
用于dMMR型晚期或复发性子宫内膜癌的一线治疗药物durvalumab联合或不联合olaparib的 cost-effectiveness分析
Jerusha Daggolu,Javeria Khalid,Hua Chen et al.
Jerusha Daggolu et al.
Background: In the phase III DUO-E trial, durvalumab with or without olaparib significantly increased survival outcomes compared to chemotherapy alone among patients with endometrial cancer. The aim of this study was to a...
Brett Hauber,Mickael Hiligsmann
Brett Hauber
Preference research is crucial in shaping effective patient-centered preventive healthcare strategies. Preventive measures such as vaccinations. screenings, and proactive treatment of asymptomatic high-risk conditions, aim to reduce future ...
Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review [0.03%]
系统评价：用于早期发现前列腺癌的磁共振检查策略的成本效益分析
Asal Sadat Niaraees Zavare,Atefeh Najafi Shahkoohi,Farhad Khalili et al.
Asal Sadat Niaraees Zavare et al.
Objectives: The objective of this study is to evaluate the cost-effectiveness of different Magnetic Resonance Imaging strategies for the early detection of prostate cancer. ...
Cost-utility analysis of Lenvatinib vs. Sorafenib in Unresectable hepatocellular carcinoma in Iran [0.03%]
伊朗不可切除肝细胞癌患者使用仑伐替尼与索拉非尼的 cost-utility 分析
Mohammad Mahdi Raeis Zadeh,Behzad Fatemi,Neshaut Mashreghi Mohammadi et al.
Mohammad Mahdi Raeis Zadeh et al.
Background: Hepatocellular carcinoma (HCC) is a global health issue and the third leading cause of cancer-related deaths. For patients with unresectable HCC (uHCC), Sorafenib and Lenvatinib, are key treatments. This study...
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations [0.03%]
自行车道的经济评价：增进人口体力活动水平的价值：系统性综述
Luiz F Andrade,Bisola Osifowora,Emma Frew
Luiz F Andrade
Background: Active travel (AT), particularly cycling, is increasingly recognized as a public health strategy to promote physical activity and prevent non-communicable diseases (NCDs). Given the substantial investments req...
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands [0.03%]
关于荷兰难治性局灶性发作癫痫患者的托匹马特成本效益分析
Nannan Li,Marian Majoie,Silvia Evers et al.
Nannan Li et al.
Objective: To assess thecost-effectiveness of cenobamate in epileptic people ith focal seizures in theNetherlands. Methods: A Markov mo...
Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies [0.03%]
肺炎球菌病的业际成本：部分经济评价研究的系统综述
Emad Almomani,Ingeborg Maria van der Putten,Ghislaine van Mastrigt et al.
Emad Almomani et al.
Introduction: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs. ...
The Economics of prevention and quality of care: policy insights from the EU's COVID-19 response [0.03%]
预防和护理质量的经济学：欧盟COVID-19应对措施的政策启示
John Yfantopoulos,Athanasios Chantzaras
John Yfantopoulos
Introduction: Prevention and quality of care are increasingly recognized as fundamental drivers of sustainable, high-performing health systems. Both have demonstrated cost-effectiveness and long-term benefits, yet remain ...